Karen L. Zaderej bought $59k of EYPT
director at EyePoint Pharmaceuticals, Inc.. 10,000 shares at an average of $5.90, traded May 16, 2025, filed May 19, 2025.
Score components
- +15RoleDirector
- +7Trade size$59k at market
- +6Relative to holdingsHoldings up 38%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +46.2%, 3m +85.7%, 6m +115.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001562180-25-003997, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 16, 2025 | POpen-market purchase Common Stock | +5,000 | $5.81 | $29k | 31,500 | May 19, 2025 |
| May 19, 2025 | POpen-market purchase Common Stock | +5,000 | $5.99 | $30k | 36,500 | May 19, 2025 |
Related signals
Other insiders at EyePoint Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | EYPTbuy EyePoint Pharmaceuticals, Inc. | Karen L. Zaderej director | $52k 10,600 shares | +28% | |
| 8Weak | EyePoint Pharmaceuticals, Inc. | Ramiro Ribeiro Chief Medical Officer | $73k 4,875 shares | -100% | |
| 6Weak | EyePoint Pharmaceuticals, Inc. | Ramiro Ribeiro Chief Medical Officer | $37k 2,437 shares | -100% | |
| 29Weak | EYPTbuy EyePoint Pharmaceuticals, Inc. | Jay S. Duker President and CEO | $20k 1,500 shares | +2% | |
| 6Weak | EyePoint Pharmaceuticals, Inc. | Ramiro Ribeiro Chief Medical Officer | $44k 2,438 shares | -100% | |
| 6Weak | EyePoint Pharmaceuticals, Inc. | Ramiro Ribeiro Chief Medical Officer | $37k 2,437 shares | -100% | |
| 21Weak | EyePoint Pharmaceuticals, Inc. | Ramiro Ribeiro Chief Medical Officer | $727k 42,544 shares | -100% | |
| 40Moderate | EyePoint Pharmaceuticals, Inc. | Cormorant Asset Management, LP other | $942k 60,000 shares | -1% | |
| 14Weak | EyePoint Pharmaceuticals, Inc. | Nancy Lurker Executive Vice Chair | $140k 9,300 shares | -4% | |
| 3Weak | EyePoint Pharmaceuticals, Inc. | Nancy Lurker Executive Vice Chair | $10k 700 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.